Category Archives: Gene therapy

European Physicians Have "Insufficient Knowledge of Biosimilars"

European physicians have insufficient knowledge of biosimilars, according to a survey carried out by the Alliance for Safe Biologic Medicines (ASBM). Only 22% of physicians consider themselves “very familiar” with this  category of medicines, and while a majority (54%) have a “basic understanding” of biosimilars, 24% of participants could not define or have not heard about […]
Also posted in Biotech, Europe, Events, Global | Tagged , , , | Leave a comment

AbbVie, Amgen, and Roche Most Exposed to Biosimilar Competition

While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.
Also posted in Biotech | Tagged , , , , | Leave a comment

Bioscience Research: China to Overtake U.S. by 2020

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
Also posted in Biotech, Emerging Markets, Global, R&D | Tagged , , , , | Leave a comment

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Also posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Global, IP, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Assessing the Value of Retrospective Studies: Real-World Data, Real-World Applications

by Sarah Ray The value of retrospective studies cannot be overstated. Retrospective studies affect many healthcare sectors, including the pharmaceutical industry and general public health. Applying these studies provides clear advantages at different points of the product life-cycle. During drug development, these studies may help clinical teams propose adaptations or even a companion diagnostic tests […]
Also posted in Global, Guest Blog, healthcare, R&D, Strategy | Tagged , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta